 |
 |
|
|
GNI is a leader in expanding the rational drug design paradigm to the entire targeting and screening process, from target selection through clinical validation. Our founding scientists are world renowned for their work in gene regulatory networks, the key to a systematic approach to understanding and controlling the protein production machinery in living cells. Unlike the previous generation of companies employing "genomics" in drug discovery that focus on the function of individual genes in isolation, GNI uses methods that leverage knowledge of genome-wide pathways and interactions among genes related to disease and normal conditions. Without network knowledge, one cannot be sure of the total effects of drugging a given molecule. Legacy drug discovery without network knowledge is dependent on a trial and error approach with a high volume of experiments and data, resulting in spiraling R&D costs with a low success rate in clinical trials. |
|
|
GNI has implemented and leveraged its technology leadership in network-guided rational drug design that integrates gene targeting, experimental systems biology, gene expression and computational modeling to develop a new class of drugs and drug targets that are more efficacious, more specific for indications, and cause less side effects for patients than drugs designed with conventional methods or even the more recent "genomic" methods of discovery.
|
|
Our Mission...
Our Value...
Our Focus...
|
